Chemotherapy was the standard of care for patients with MCC until anti-PD-L1 antibody avelumab was approved in 2017 by the FDA and European Medicines Agency (EMA) [36,53,54,55]. This evidence concerns the gene CD274 and Merkel cell skin cancer.